<SEC-DOCUMENT>0001746473-25-000128.txt : 20250609
<SEC-HEADER>0001746473-25-000128.hdr.sgml : 20250609
<ACCEPTANCE-DATETIME>20250609204355
ACCESSION NUMBER:		0001746473-25-000128
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250605
FILED AS OF DATE:		20250609
DATE AS OF CHANGE:		20250609

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Krognes Steve E.
		CENTRAL INDEX KEY:			0001666236
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39303
		FILM NUMBER:		251035731

	MAIL ADDRESS:	
		STREET 1:		863 MITTEN ROAD, SUITE 102
		CITY:			BURLINGAME
		STATE:			CA
		ZIP:			94010

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PLIANT THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001746473
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				474272481
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		331 OYSTER POINT BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-481-6770

	MAIL ADDRESS:	
		STREET 1:		331 OYSTER POINT BOULEVARD
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1749516225.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-06-05</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001746473</issuerCik>
        <issuerName>PLIANT THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>PLRX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001666236</rptOwnerCik>
            <rptOwnerName>Krognes Steve E.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O PLIANT THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>331 OYSTER POINT BOULEVARD</rptOwnerStreet2>
            <rptOwnerCity>SOUTH SAN FRANCISCO</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94080</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Common Stock (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.61</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-06-05</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>30000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-06-05</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>30000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>30000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">25% of the shares subject to such option vest and become exercisable on October 1, 2025, January 1, 2026, and April 1, 2026, respectively,  and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 5, 2025 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Jennifer Woo, attorney-in-fact</signatureName>
        <signatureDate>2025-06-09</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poa_krognes.txt
<DESCRIPTION>EX-24
<TEXT>
LIMITED POWER OF ATTORNEY

	The undersigned hereby constitutes and appoints each of
Keith Cummings, Johannes (Hans) Hull, Jennifer Woo and Scott Peters,
signing singly, and with full power of substitution, the undersigned's
true and lawful attorney-in-fact to:

	(1)	execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer/director of Pliant Therapeutics, Inc., a Delaware
corporation (the "Company"), from time to time the following
U.S. Securities and Exchange Commission ("SEC") forms: (i) Form ID,
including any attached documents (such as Update Passphrase Authentication),
to effect the assignment of codes to the undersigned to be used in the
transmission of information to the SEC using the EDGAR System;
(ii) Form 3, Initial Statement of Beneficial Ownership of Securities,
including any attached documents; (iii) Form 4, Statement of Changes
in Beneficial Ownership of Securities, including any attached documents;
(iv) Form 5, Annual Statement of Beneficial Ownership of Securities
in accordance with Section 16(a) of the Securities Exchange Act of 1934,
as amended, and the rules thereunder, including any attached documents;
(v) Schedules 13D and 13G; and (vi) amendments of each thereof, in accordance
with the Securities Exchange Act of 1934, as amended, and the rules thereunder,
including any attached documents;

	(2)	do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such
Form 3, 4 or 5, Schedule 13D or 13G, or any amendment(s) thereto
and timely file such form(s) with the SEC and any securities exchange,
national association or similar authority; and

	(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact
on behalf of the undersigned pursuant to this Power of Attorney
shall be in such form and shall contain such terms and conditions as such
attorney-in-fact may approve in such attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact, acting singly,
full power and authority to do and perform any and every act and thing
whatsoever requisite, necessary or proper to be done in the exercise of any of
the rights and powers herein granted, as fully to all intents and
purposes as the undersigned might or could do if personally present,
with full power of substitution or revocation, hereby ratifying and confirming
all that such attorney-in-fact, or such attorney-in-fact's substitute or
substitutes, shall lawfully do or cause to be done by virtue of this
power of attorney and the rights and powers herein granted.
The undersigned acknowledges that the foregoing attorneys-in-fact,
in serving in such capacity at the request of the undersigned, are not
assuming, nor is the Company assuming, any of the undersigned's
responsibilities to comply with Section 16 or Regulation 13D-G of the
Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees
to indemnify the attorneys-in-fact and the Company from and against
any demand, damage, loss, cost or expense arising from any false or misleading
information provided by the undersigned to the attorneys-in-fact.

	This Power of Attorney shall remain in full force and effect until
the undersigned is no longer required to file such forms with respect to
the undersigned's holdings of and transactions in securities issued by
the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.  This Power of Attorney
supersedes any prior power of attorney in connection with the undersigned's
capacity as an officer and/or director of the Company.  This Power of Attorney
shall expire as to any individual attorney-in-fact if such attorney-in-fact
ceases to be an employee of, or legal counsel to, the Company.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of 6/5/2025.

							/s/ Steve Krognes
							Signature


							Steve Krognes
							Print Name
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
